Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium Tc 99m zoledronate
- Development stage
- Unknown
- Lead developer
- Pharm-Sintez
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Rezoscan is a diagnostic radiopharmaceutical consisting of the bisphosphonate zoledronic acid labeled with the radionuclide technetium-99m (99mTc). Developed by Pharm-Sintez, it is utilized as an imaging agent for skeletal scintigraphy and Single Photon Emission Computed Tomography (SPECT). The mechanism of action relies on the high affinity of the zoledronic acid moiety for hydroxyapatite crystals in bone tissue, particularly in areas of increased bone turnover and osteoblastic activity. Once localized to the skeleton, the gamma-emitting 99mTc isotope allows for the visualization of pathological bone changes. Rezoscan is primarily indicated for the detection of bone metastases in patients with malignant tumors, as well as for identifying pathological changes associated with osteomyelitis, bone tuberculosis, and arthritis.
- Brand names
- Rezoscan
- Other names
- Rezoscan 99mTcRezoscan99mTcRezoscan-99mTcTechnetium-99m-labeled zoledronic acidTechnetium99m-labeled zoledronic acidTechnetium 99m-labeled zoledronic acid99mTc-zoledronic acid99mTc-ZOL
Beyond the preview
Go deeper on technetium Tc 99m zoledronate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium Tc 99m zoledronate.